세계의 성교통 치료 시장 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별
Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens, Corticosteroids, Antibiotics, and Others), By Route of Administration, By Distribution Channel, By Geography
상품코드
:
1482456
리서치사
:
Coherent Market Insights
발행일
:
2024년 04월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계 성교통 치료 시장 규모는 2024년 7억 5,410만 달러로 2024-2031년 연평균 4.6% 성장하여 2031년에는 10억 3,540만 달러에 달할 것으로 예측됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2023년 |
2024년 시장 규모 |
7억 5,410만 달러 |
| 실적 데이터 |
2019-2023년 |
예측 기간 |
2024-2031년 |
| 예측 기간, 2024-2031년 CAGR: |
4.60% |
2031년 금액 전망 |
10억 3,540만 달러 |
그림. 성교통 치료 시장 점유율(%), 지역별, 2024년
성교통은 전 세계적으로 여성에게 널리 퍼져 있는 문제입니다. 삽입 중 또는 삽입 후 골반 부위 또는 그 주변의 통증이 특징이며 신체적, 심리적 영향을 미칩니다. 정확한 원인은 사람마다 다르지만, 일반적인 원인으로는 질 감염, 자궁내막증, 심리적 요인, 출산 시 골반 주변 손상 등이 있습니다. 치료하지 않고 방치하면 삶의 질과 성관계에 악영향을 미칠 수 있습니다. 성기능 장애 치료 시장은 통증을 완화하고 친밀감을 회복하는 의약품 및 의료기기 옵션으로 구성되어 있습니다. 호르몬 요법, 물리치료, 최소침습 수술 등 치료 분야의 발전으로 성기능 장애를 효과적으로 관리할 수 있는 선택지가 확대되고 있습니다.
시장 역학:
치료 옵션에 대한 인식이 높아지고 여성의 섹슈얼리티에 대한 논의가 활발해지면서 성교통 치료 시장이 성장하고 있습니다. 여성 건강 문제와 관련된 역사적 낙인이 점차 줄어들고 있으며, 환자들이 치료를 받을 수 있는 권한이 강화됨에 따라 점차 감소하고 있습니다. 비침습적, 비약물적 대안에 대한 수요가 증가함에 따라 이 분야에서 물리치료 도구 및 의료기기의 기회가 확대되고 있습니다. 그러나 새로운 기술에 수반되는 높은 비용은 시장 확대를 어느 정도 제한할 수 있습니다. 일부 지역에서는 문화적, 사회적 장벽으로 인해 도움을 요청하는 행동을 계속 방해하고 있습니다. 한편, 골반저 장애와 신경학적 문제가 있는 고령화 사회는 시장 진입 기업들에게 새로운 전망을 가져다 줄 것입니다.
본 조사의 주요 특징
- 이 보고서는 2023년을 기준 연도로 하여 예측 기간(2024-2031년)의 시장 규모(100만 달러)와 연평균 성장률(CAGR)을 통해 세계 성교통증 치료제 시장을 상세히 분석합니다.
- 또한 다양한 부문에 걸친 잠재적 수익 성장 기회를 밝히고, 이 시장에 대한 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략 등에 대한 중요한 인사이트도 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 성교통 치료 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 성교통 치료 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계 성교통 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 시장 동향
- 최근의 동향
- 인수와 제휴 시나리오
- 제품 발매/승인
- 자금 조달과 투자
- 환급 시나리오
- PEST 분석
- Porters 분석
제4장 세계의 성교통 치료 시장 - COVID-19 팬데믹의 영향
- 전체적인 영향
- 정부 이니셔티브
- COVID-19에 의한 시장에 대한 영향
제5장 세계의 성교통 치료 시장, 약제 유형별, 2019-2031년(100만 달러)
- 선택적 에스트로겐 수용체 모듈레이터
- 에스트로겐(기타 질제)
- 코르티코스테로이드
- 항생제
- 기타
제6장 세계의 성교통 치료 시장, 투여 경로별, 2019-2031년(100만 달러)
제7장 세계의 성교통 치료 시장, 유통 채널별, 2019-2031년(100만 달러)
- 소매 약국
- 병원 약국
- E-Commerce
- 기타
제8장 세계의 성교통 치료 시장, 지역별, 2019-2031년(100만 달러)
제9장 경쟁 상황
- 기업 개요
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International
제10장 애널리스트의 견해
제11장 참고문헌과 조사 방법
ksm
영문 목차
The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.
| Report Coverage |
Report Details |
| Base Year: |
2023 |
Market Size in 2024: |
US$ 754.1 Mn |
| Historical Data for: |
2019 To 2023 |
Forecast Period: |
2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: |
4.60% |
2031 Value Projection: |
US$ 1,035.4 Mn |
Figure. Dyspareunia Treatment Market Share (%), By Region 2024
Dyspareunia, or painful sexual intercourse, is a prevalent issue that affects women globally. It is characterized by pain in the pelvic region or surrounding area during or after penetration, and has physical as well as psychological implications. The exact causes may vary from person to person, but common contributors include vaginal infections, endometriosis, psychological factors, and pelvic area injuries during childbirth. If left untreated, it can have a negative impact on quality of life and sexual relationships. The dyspareunia treatment market consists of pharmaceutical and medical device options that provide relief from pain and help restore intimacy. Advancements in therapeutic areas like hormonal therapy, physical therapy, and minimally invasive procedures are expanding choices for managing this condition effectively.
Market Dynamics:
Rising awareness about available treatment choices and more open discussion of female sexuality are driving the dyspareunia treatment market. Historical stigma around women's health issues is gradually reducing as patients feel more empowered to seek care. Growing demand for non-invasive and non-drug alternatives to pharmacological management is opening up opportunities for physical therapy tools and medical devices in this space. However, high costs associated with newer technologies could restrict market expansion to some degree. Cultural and social barriers continue to hamper help-seeking behavior in certain regions as well. Meanwhile, an aging population presenting with pelvic floor disorders and neurological issues presents new prospects for market participants.
Key Features of the Study:
- This report provides an in-depth analysis of the global dyspareunia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dyspareunia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study includes Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dyspareunia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyspareunia treatment market
Detailed Segmentation-
- Drug Type:
- Selective Estrogen Receptor Modulators
- Estrogens (Miscellaneous Vaginal Agents)
- Corticosteroids
- Antibiotics
- Others
- Route of Administration:
- Oral
- Vaginal Inserts
- Others
- Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
- Others
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Product Launches/Approvals
- Fundings and Investments
- Reimbursement Scenario
- PEST Analysis
- Porter's Analysis
4. Global Dyspareunia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Dyspareunia Treatment Market, By Drug Type, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Selective Estrogen Receptor Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Estrogens (Miscellaneous Vaginal Agents)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Dyspareunia Treatment Market, By Route of Administration, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Vaginal Inserts
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Dyspareunia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- E-commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Dyspareunia Treatment Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Lupin*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Duchesnay Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AMAG Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- TherapeuticsMD, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sumitomo Pharma Co., Ltd.,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Myovant Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Shionogi & Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Millicent Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cosette Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mundipharma International
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
관련자료
